https://www.bigmoleculewatch.com/2023/08/17/sarepta-and-catalent-file-answers-in-regenxbio-v-sarepta-litigation/
Sarepta and Catalent File Answers in REGENXBIO v. Sarepta Litigation - Big Molecule Watch
Aug 18, 2023 - As we previously reported, REGENXBIO Inc. and the Trustees of the University of Pennsylvania filed suit in Delaware against Sarepta Therapeutics, Inc., Sarepta...
sareptacatalentfileanswersregenxbio
https://www.politicaldigestnauru.com/article/898587934-rosen-a-leading-investor-rights-law-firm-encourages-regenxbio-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel...
investor rightslaw firmrosenleadingencourages
https://public.com/stocks/rgnx/after-hours
Trade REGENXBIO (RGNX) Stock After-hours on Public.com
Trade REGENXBIO (RGNX) stock after hours on Public.com from 4:00 pm to 8:00 pm ET. Track RGNX's after-hours price, range, and movement after the market closes.
after hourspublic comtraderegenxbiorgnx
https://stockanalysis.com/stocks/rgnx/financials/balance-sheet/
REGENXBIO (RGNX) Balance Sheet
Detailed annual and quarterly balance sheet for REGENXBIO (RGNX), including cash, debt, assets, liabilities, and book value.
balance sheetregenxbiorgnx
https://www.medicaldesignsourcing.com/regenxbio-inks-deal-with-abbvie-to-pursue-development-of-rgx-314/
Regenxbio inks deal with AbbVie to pursue development of RGX-314 - Medical Design Sourcing
Nov 9, 2021 - Regenxbio (NSDQ:RGNX) has closed a license agreement with AbbVie (NYSE:ABBV) to develop RGX-314, a vascular endothelial growth factor inhibitor. The drug has...
medical design sourcingregenxbioinksdealabbvie
https://www.ophthalmologymanagement.com/news/2025/regenxbio-completes-enrollment-in-phase-3-pivotal-gene-therapy-trials-for-wet-amd/
Regenxbio Completes Enrollment in Phase 3 Pivotal Gene Therapy Trials for Wet AMD | Ophthalmology...
Oct 6, 2025 - Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through...
gene therapywet amdregenxbiocompletesenrollment
https://www.prnewswire.com/news-releases/regenxbio-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--rgnx-302740174.html
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your...
/PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for...
securities law violationscontact theto discussregenxbioinc
https://stocks-assistant.kreatebots.com/regenxbio-inc/2025/q4/summary
REGENXBIO-INC 2025 Q4 - Summary | Stocks Assistant
Get detailed insights about REGENXBIO-INC for Q4 of 2025.
regenxbioincsummarystocksassistant
https://www.clinicaltrialsarena.com/news/regenxbio-amd-gene-trial-enrolment/
REGENXBIO completes wet AMD gene therapy trial enrolment
Oct 7, 2025 - REGENXBIO has concluded participant enrolment in the pivotal ATMOSPHERE and ASCENT trials, which are assessing surabgene lomparvovec (sura-vec, ABBV-RGX-314)...
wet amdgene therapyregenxbiocompletestrial